30 October 2026 (Navroze Bureau) India’s growing nutraceutical and health supplement market has come under scrutiny after the Advertising Standards Council of India (ASCI) found that 60 advertisements violated its advertising code because their health claims were not adequately supported by scientific evidence.
The findings were published in a report titled A Pill for Thought: Review of Health and Wellness Claims in Nutraceutical Advertising, released on October 28, 2026. The review examined 61 advertisements identified between July and September 2026. Investigations into 60 advertisements had been completed when the report was released, and all 60 were found to violate the ASCI Code.
The findings have raised questions about how supplement companies promote products promising weight loss, younger-looking skin, respiratory benefits and improvements in chronic health conditions.
The issue is particularly important because nutraceuticals in India are regulated as food products rather than medicines. Companies cannot freely advertise them as treatments or cures for diseases.
What Did the ASCI Report Find?
According to the report, 60 completed cases failed to meet the required advertising standards. Of these, 29 advertisers did not contest ASCI’s objections, while the remaining 31 challenged the findings but failed to provide sufficient evidence to substantiate their claims.
The advertisements covered several categories, including weight management, skincare, anti-ageing, blood sugar control, respiratory health and cholesterol management.
Some of the claims highlighted in the review included promises to lose six kilograms in 60 days, make skin appear seven years younger, reverse asthma or polycystic ovarian disease (PCOD), and provide 300% stronger protection against ultraviolet radiation.
ASCI raised concerns about the scientific basis of these claims, particularly where advertisers could not demonstrate that the finished product delivered the advertised results.
The findings relate to advertising-code violations and inadequate substantiation. They do not automatically establish that every product involved was unsafe or ineffective for all uses.
Why Ingredient-Level Research Is Not Enough
One of the major concerns identified in the report was the use of scientific studies on individual ingredients to promote finished commercial products.
For example, a company may refer to research suggesting that a particular botanical extract or vitamin has a potential health benefit. However, that research does not automatically prove that a supplement containing the ingredient will produce the same result.
The effectiveness of a finished product can depend on several factors, including the quantity of each ingredient, formulation, absorption, bioavailability, interactions between ingredients and duration of use.
A study conducted using a particular dose cannot automatically support the same claim for a product containing a different quantity or formulation.
ASCI emphasised the need for evidence that directly supports the advertised product and the specific benefit being promised. Claims involving rapid weight loss, disease reversal and dramatic physical changes require particularly careful substantiation.
What India’s FSSAI Rules Say About Nutraceuticals
The Food Safety and Standards Authority of India (FSSAI) regulates health supplements and nutraceuticals under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016.
These regulations cover product categories, permitted ingredients, composition, usage conditions and labelling requirements.
An important distinction under the framework is that nutraceuticals are intended to provide nutritional or physiological benefits. They are not ordinary medicines and cannot automatically be promoted as products that diagnose, treat, cure or prevent diseases.
This means that a supplement cannot simply claim to reverse asthma, cure PCOD or replace prescribed diabetes medication because one of its ingredients has been studied for a possible health benefit.
Companies must follow the applicable conditions for permitted claims and ensure that their product descriptions and advertisements do not mislead consumers.
FSSAI’s October 2026 Advisory on Botanical Ingredients
The issue has gained further importance following an FSSAI advisory issued on October 15, 2026.
The advisory reminded manufacturers and food business operators dealing with nutraceuticals, health supplements and certain specialised food products about mandatory labelling requirements for plant-based and botanical ingredients.
These requirements include identifying the plant part used and providing applicable cautionary statements and warnings for relevant ingredients.
Such information is important because herbal and botanical substances can have physiological effects, cause adverse reactions or interact with medicines. The fact that an ingredient is described as natural does not automatically make it safe for everyone.
FSSAI has warned that non-compliance can invite regulatory action under the Food Safety and Standards Act, 2006, including applicable penalties and action against licences.
What the Advertising and Claims Regulations Require
Apart from the 2016 nutraceutical regulations, the Food Safety and Standards (Advertising and Claims) Regulations, 2018, establish requirements for claims made about food products.
Under this framework, claims must meet applicable conditions and be supported by appropriate scientific evidence. Companies cannot make misleading statements, exaggerate benefits or create an impression that goes beyond what the available research establishes.
Certain nutritional, health and disease-risk-reduction claims may be used only when the relevant regulatory conditions are satisfied. Some claims may require prior approval from FSSAI.
For example, a permitted claim about the role of a nutrient in normal body functioning is different from a promise that a supplement can cure a medical condition.
A disclaimer in small print does not automatically make an exaggerated or misleading headline acceptable.
Role of ASCI and Consumer Protection Authorities
ASCI is a self-regulatory organisation that examines advertisements under its code. It is not a government food regulator, but its reviews can result in advertisers being asked to modify or withdraw advertisements.
Government authorities have separate enforcement powers.
The Central Consumer Protection Authority (CCPA), operating under the Consumer Protection Act, 2019, can take action against misleading advertisements and unfair trade practices. The CCPA’s 2022 guidelines also establish standards for truthful advertising and endorsements.
The guidelines provide for penalties of up to ₹10 lakh for misleading advertisements and up to ₹50 lakh for subsequent contraventions, subject to the applicable legal provisions.
Together, the frameworks address different aspects of the problem: product safety and labelling, scientific substantiation of health claims, and protection against misleading advertising.
What Consumers Should Check Before Buying Supplements
The ASCI findings serve as a reminder that consumers should not rely only on advertisements, influencer recommendations or dramatic before-and-after photographs when choosing health supplements.
Before purchasing a nutraceutical, consumers should check the ingredient list, recommended dosage, manufacturer details, warnings and applicable regulatory information.
Promises of guaranteed weight loss, disease reversal, instant anti-ageing results or the ability to replace prescription medicines should be treated with caution.
People with chronic illnesses, pregnant or breastfeeding individuals, and those taking prescription medicines should consult a qualified healthcare professional before using supplements.
Most importantly, nutraceuticals should not be used as substitutes for prescribed treatment or medical advice.
A Growing Need for Responsible Health Advertising
India’s nutraceutical market continues to attract consumers interested in fitness, preventive healthcare, nutrition and wellness. However, the latest ASCI report highlights the gap that can emerge between scientific evidence and marketing promises.
The finding that all 60 completed advertisement reviews violated the ASCI Code underlines the importance of stronger scientific substantiation and responsible communication by supplement companies.
For consumers, the message is straightforward: an impressive health claim is not proof of effectiveness. Products should be judged by reliable evidence, transparent labelling and appropriate medical guidance rather than advertising promises.